About novonesis (novozymes a/s) - NVZMY
Novonesis (Novozymes A/S) engages in the era of biosolutions. It innovate and develop transformative biosolutions that improve the way the world produces, consumes, and lives. The company was founded on January 29, 2024 is headquartered in Lyngby, Denmark.
NVZMY At a Glance
Novonesis (Novozymes A/S)
Biologiens Vej 2
Lyngby, North Denmark 2800
| Phone | N/A | Revenue | 4.69B | |
| Industry | Chemicals: Specialty | Net Income | 658.64M | |
| Sector | Process Industries | 2025 Sales Growth | 13.156% | |
| Fiscal Year-end | 12 / 2026 | Employees | 11,641 | |
| View SEC Filings |
NVZMY Valuation
| P/E Current | 42.35 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 45.362 |
| Price to Sales Ratio | 6.39 |
| Price to Book Ratio | 2.343 |
| Price to Cash Flow Ratio | 21.75 |
| Enterprise Value to EBITDA | 20.089 |
| Enterprise Value to Sales | 7.068 |
| Total Debt to Enterprise Value | 0.106 |
NVZMY Efficiency
| Revenue/Employee | 403,073.301 |
| Income Per Employee | 56,579.175 |
| Receivables Turnover | 4.364 |
| Total Asset Turnover | 0.252 |
NVZMY Liquidity
| Current Ratio | 0.723 |
| Quick Ratio | 0.442 |
| Cash Ratio | 0.108 |
NVZMY Profitability
| Gross Margin | 47.847 |
| Operating Margin | 20.827 |
| Pretax Margin | 18.037 |
| Net Margin | 14.037 |
| Return on Assets | 3.54 |
| Return on Equity | 5.416 |
| Return on Total Capital | 4.046 |
| Return on Invested Capital | 4.801 |
NVZMY Capital Structure
| Total Debt to Total Equity | 27.686 |
| Total Debt to Total Capital | 21.683 |
| Total Debt to Total Assets | 17.25 |
| Long-Term Debt to Equity | 12.012 |
| Long-Term Debt to Total Capital | 9.407 |